There is no loud knocking. It comes like a whisper—a single lymph node swelling, a brief feeling of exhaustion, or perhaps a recurring fever that defies explanation. For many people, Castleman disease remains silent until something prompts them to look for answers. It is a very elusive condition.
A man once complained of mild chest pressure when he arrived at the hospital. A scan revealed what appeared to be a benign mass nestled between the lungs and the heart. It turned out that unicentric Castleman disease was what the surgeons had removed. It had simply sat there, undetected, until it vanished without spreading or leaving a trail of symptoms.
Castleman Disease – Key Facts Table
| Category | Details |
|---|---|
| Type | Rare lymphoproliferative disorder (non-cancerous) |
| Subtypes | Unicentric (UCD) and Multicentric (MCD) |
| Common Symptoms (UCD) | Often asymptomatic; may include swelling or pressure-related discomfort |
| Common Symptoms (MCD) | Fever, fatigue, night sweats, weight loss, enlarged organs |
| Known Triggers | Interleukin-6 overproduction, HHV-8 virus (in some cases), idiopathic |
| Risk Factors | HIV infection (for HHV-8 cases); no clear risks for other subtypes |
| Diagnostic Methods | Lymph node biopsy, blood tests, imaging (CT, PET) |
| Treatment (UCD) | Surgical removal of affected lymph node (often curative) |
| Treatment (MCD) | IL-6 inhibitors (siltuximab, tocilizumab), rituximab, chemotherapy |
| Prognosis | Excellent for UCD; improving significantly for MCD with newer therapies |
| Source |
Such restraint does not apply to multicentric Castleman disease. Like a string of erratic sparks, it disperses its influence throughout the lymphatic system. This form is characterized by persistent fevers, exhausting fatigue, and night sweats that seep through bedding. Multiple stations experience lymph node swelling, which impacts organs, blood counts, and even nerve function.
Things get more complicated when HHV-8, a herpesvirus strain, comes into play, particularly in HIV-positive individuals. The virus causes the production of IL-6, which overwhelms the immune system. However, for many patients, especially those with idiopathic MCD, there is chaos without a clear cause—neither a virus nor an infection.
In recent years, treatment has significantly improved. Siltuximab and tocilizumab, two monoclonal antibodies that target IL-6, have demonstrated remarkable efficacy in symptom reduction and disease progression slowing. By muting the molecule at the center of the spiral, they quiet the storm. Rituximab, an antibody that targets B-cells, has proven particularly useful in cases associated with HHV-8. Chemotherapy is still a blunt but occasionally required tool when everything else has failed.
However, many patients characterize the process of reaching that point—diagnosis, classification, and treatment—as convoluted and fragmented.
There isn’t always a single, striking symptom that indicates the disease. Some people begin with inexplicable weight loss or a general feeling of unwellness. Others report experiencing odd limb sensations or obvious swelling in the area of their neck or groin. Imaging provides hints but not solutions. Bloodwork doesn’t solve the puzzle; it just adds to it. The biopsy, which involves closely examining the tissue, is what ultimately provides insight.
Even so, careful interpretation is required. Castleman disease can look like autoimmune diseases or cancers like lymphoma. A pattern of cellular crowding that doesn’t quite fit any other description, vascular alterations, and aberrant follicular dendritic cells are the telltale signs that pathologists need to watch out for. It’s a diagnosis that many physicians believe requires patience and accuracy.
Hospitals are now better equipped to identify and treat these cases thanks to the integration of multidisciplinary teams, which include immunologists, infectious disease specialists, and oncologists. Delays in diagnosis have been considerably decreased by the move from fragmented care to collaborative approaches.
After almost two years of sporadic symptoms, a young woman was eventually diagnosed with idiopathic MCD, according to a clinical note I once read. Fatigue, leg swelling, dry rashes, weight loss, and an enlarged spleen were all listed on her chart, which looked like a shuffled deck. The greatest relief she experienced was not from the medication, but rather from being understood at last.
In contrast, Unicentric Castleman exhibits much more predictable behavior. Surgery is frequently used for both diagnosis and treatment, and it usually affects a single lymph node station. The cut, confirm, resolve method has a certain elegance to it. However, difficulties still occur here. When the mass is tucked away in awkward locations, it may cause discomfort, obstruct breathing, or compress adjacent organs.
The results for UCD are fortunately very good. Many patients go on to lead healthy, normal lives free from recurrence. And although MCD is still a more formidable foe, the course has shifted. The prognosis for idiopathic MCD was extremely uncertain just ten years ago. The situation is now much better thanks to the creation of targeted treatments and continuing research networks like the CDCN.
Better storytelling—patients, researchers, and advocates sharing what they’ve learned—is partly responsible for that optimism. Despite the disease’s rarity, teamwork is expanding quickly. A lot of data is being collected. The trials are progressing. Individuals with Castleman disease are now essential to the learning and adaptation of the medical community, not just inconspicuous participants in a little-known area of immunology.
This change is reflected in many aspects of the science. Researchers are identifying trends that may eventually result in complete prevention by concentrating on inflammatory markers, immune signaling, and viral interactions. Furthermore, this research contributes to a wider comprehension of how the immune system can become dangerously overactive, going beyond Castleman. Such information is especially helpful for both physicians and patients.
Assumptions are challenged by Castleman disease. It teaches practitioners to look beyond traditional frameworks, listen intently, and read carefully. For patients, it serves as a reminder of a lesson that medicine occasionally overlooks: something is not necessarily to be disregarded just because it is uncommon.
The tools have become sharper in recent years. The path is now more obvious. However, Castleman disease’s questions about immunity, balance, and the cost of delay continue to reverberate, subtly reminding the system to remain vigilant.
And that awareness could be crucial for those dealing with this diagnosis right now.
